PTI Proteostasis Therapeutics Inc.

1.38
-0.04  -3%
Previous Close 1.42
Open 1.39
Price To Book 1.35
Market Cap 71,963,765
Shares 52,147,656
Volume 611,650
Short Ratio
Av. Daily Volume 994,602
Stock charts supplied by TradingView

NewsSee all news

  1. Proteostasis Therapeutics Announces In Vitro Data for PTI-129 as Potential Treatment Candidate for COVID-19

    BOSTON, June 1, 2020 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic

  2. Proteostasis Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

    BOSTON, May 15, 2020 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic

  3. Proteostasis Therapeutics to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference

    BOSTON, May 13, 2020 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic

  4. Vasomune Therapeutics Appoints Meenu Chhabra to its Board of Directors

    Industry Leader Joins Vasomune's Board of Directors as the Company Transitions to Clinical Development of AV-001 for the Treatment of COVID-19/pathogen-induced ARDS Vasomune Therapeutics, Inc., an early stage

  5. Proteostasis Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Corporate Update

    BOSTON, March 10, 2020 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 28-day data released December 11, 2017 - showed improvements in FEV1 of 5.2%. Phase 2 28-day data released December 11, 2017 - showed improvements in FEV1 of 5.2%.
PTI-428
Cystic fibrosis
Development to be discontinued due to lack of efficacy - March 25, 2019.
PTI-801 + Symdeko
Cystic fibrosis
Phase 2 negative data released December 17, 2019. Mean changes in ppFEV1 were not statistically significant in the heterozygous population. Phase 3 trial to be initiated in 2020.
PTI-428 + PTI-801 + PTI-808
Cystic fibrosis
Development to be discontinued due to lack of efficacy.
PTI-428 + Symdeko
Cystic fibrosis

Latest News

  1. Proteostasis Therapeutics Announces In Vitro Data for PTI-129 as Potential Treatment Candidate for COVID-19

    BOSTON, June 1, 2020 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic

  2. Proteostasis Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

    BOSTON, May 15, 2020 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic

  3. Proteostasis Therapeutics to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference

    BOSTON, May 13, 2020 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic

  4. Vasomune Therapeutics Appoints Meenu Chhabra to its Board of Directors

    Industry Leader Joins Vasomune's Board of Directors as the Company Transitions to Clinical Development of AV-001 for the Treatment of COVID-19/pathogen-induced ARDS Vasomune Therapeutics, Inc., an early stage

  5. Proteostasis Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Corporate Update

    BOSTON, March 10, 2020 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic

  6. Proteostasis Therapeutics Announces New Publication on the Mechanism of Action of a Novel Class of CFTR Modulators Called Amplifiers in the Journal of Cystic Fibrosis

    BOSTON, Feb. 25, 2020 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to

  7. Proteostasis Therapeutics and CF Europe Announce Completion of Patient Enrollment for CHOICES, the First-Ever Personalized Medicine-Based Study in Cystic Fibrosis

    BOSTON, Feb. 24, 2020 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic

  8. Proteostasis Therapeutics Announces Keystone Symposia Presentation of Organoid Study from More than 300 Adult CF Patients

    BOSTON, Jan. 22, 2020 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic

  9. Proteostasis Therapeutics Regulatory Update Following Scientific Advice Meeting with MHRA

    BOSTON, Jan. 13, 2020 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic

  10. Proteostasis Therapeutics Announces Positive Phase 2 Topline Results from Proprietary CFTR Modulator Combinations in F508del Homozygous Cystic Fibrosis Patients

    BOSTON, Dec. 17, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic

  11. Proteostasis Therapeutics to Initiate First Ever Personalized Medicine-Based Clinical Trial, CHOICES, in European CF Patients with Genotypes Ineligible for Approved CFTR Modulators

    BOSTON, Dec. 11, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic

  12. Proteostasis Therapeutics to Present at the Piper Jaffray 31st Annual Healthcare Conference

    BOSTON, Dec. 3, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic

  13. Proteostasis Therapeutics Regains Compliance with Nasdaq Listing Standards

    BOSTON, Dec. 2, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic

  14. Proteostasis Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    BOSTON, Nov. 7, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic

  15. Proteostasis Therapeutics Announces Completion of Enrollment in Global Phase 2 Study in Cystic Fibrosis

    BOSTON, Nov. 6, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic

  16. Proteostasis Therapeutics Announces Presentations Highlighting its CFTR Modulators at the North American Cystic Fibrosis Conference

    BOSTON, Oct. 24, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic

  17. Proteostasis Therapeutics to Present at the 2019 Cantor Global Healthcare Conference

    BOSTON, Sept. 26, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic

  18. Proteostasis Therapeutics Announces Presentation at the UK Cystic Fibrosis Conference

    BOSTON, Sept.19, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic